2020年美国风湿病学会《痛风管理指南》解读  

2020 American College of Rheumatology guideline for the management of gout: an interpretation

作　　者：李秀[1] 张姬慧[1] 聂英坤[1] LI Xiu;ZHANG Jihui;NIE Yingkun(Department of Rheumatology,The Second Affiliated Hospital of Harbin Medical University,Harbin 150086,P.R.China)

机构地区：[1]哈尔滨医科大学附属第二医院风湿免疫科,哈尔滨150086

出　　处：《中国循证医学杂志》2021年第4期376-382,共7页Chinese Journal of Evidence-based Medicine

摘　　要：痛风是最常见的炎性关节炎,其特征是尿酸盐增高和单钠尿酸盐(MSU)晶体沉积在组织中,引起关节炎、软组织肿块(即痛风石)、肾结石和尿酸盐肾病,对患者健康相关生活质量有重大影响。美国风湿病学会(ACR)于2020年6月发布了《痛风管理指南》。该指南提出了42条建议(包括16条强推荐建议),阐述了降尿酸治疗(ULT)的适应症、启动方法、持续管理、痛风发作、痛风患者和无症状高尿酸血症患者的生活方式和其他药物治疗策略。本文对其进行解读,以期为临床实践提供参考。Gout is the most common inflammatory arthritis,which is characterized by elevated urate and monosodium urate(MSU)crystal deposition in tissues,leading to arthritis,soft-tissue masses(tophi),nephrolithiasis,and urate nephropathy.It has a major impact on health-related quality of life.The American College of Rheumatology(ACR)published ACR guidelines for the management of gout in June 2020,in which 42 recommendations(including 16 strong recommendations)were generated.The guideline described indications for urate-lowering therapy(ULT),approaches to initiating,ongoing management,gout flares,and lifestyle and other medication strategies in patients with gout and in individuals with asymptomatic hyperuricemia.This paper interprets it to provide references for clinical practice.

关 键 词：痛风 降尿酸 治疗 管理 指南解读 

分 类 号：R589.7[医药卫生—内分泌]